GSK PLC-SPON ADR (GSK:NYSE)
$50.01 -0.04 (-0.0799%)
Analysed GSK PLC-SPON ADR (GSK:NYSE) News Sources
GHO Capital appoints Vivid Sehgal as Operating Partner
08-09-2026
yahoo.com
Can GSK’s Hepatitis B Breakthrough Become a £2 Billion Opportunity?
05-09-2026
yahoo.com
Unlocking Opportunity: Dominate the Cancer Vaccine Market with Confidence Now Available. Tracks 960+ Organizations and 2,100+ Drugs Across the Full Cancer Vaccine Pipeline
07-09-2026
yahoo.com
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
07-09-2026
yahoo.com
GSK’s mRNA Flu Vaccine Shows Promise, But Can It Deliver Late-Stage?
11-09-2026
yahoo.com
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff
13-09-2026
marketbeat.com
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
14-09-2026
yahoo.com
GSK splashes up to $750m on experimental cancer therapy
15-09-2026
proactiveinvestors.com
GSK Cuts 641 Jobs in Vaccine Manufacturing Restructuring
15-09-2026
yahoo.com
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
15-09-2026
yahoo.com
What is the current price of GSK PLC-SPON ADR (GSK:NYSE)?
The current price of GSK PLC-SPON ADR (GSK:NYSE) is $50.01.
GSK PLC-SPON ADR (GSK:NYSE) absolute price change since previous trading day?
The absolute price change of GSK PLC-SPON ADR (GSK:NYSE) since the previous trading day is $-0.04.
GSK PLC-SPON ADR (GSK:NYSE) percentage price change since previous trading day?
The percentage price change of GSK PLC-SPON ADR (GSK:NYSE) since the previous trading day is -0.0799%.
What is the most recent average sentiment score for GSK PLC-SPON ADR (GSK:NYSE)?
The most recent average sentiment score for GSK PLC-SPON ADR (GSK:NYSE) is 73 out of 100.
What is the most recent average sentiment for GSK PLC-SPON ADR (GSK:NYSE)?
The most recent sentiment for GSK PLC-SPON ADR (GSK:NYSE) is .
SEC-8K** Filing Available For GSK PLC-SPON ADR (GSK:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.